Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This paper describes the high-throughput proteomic analysis of the dorsolateral prefrontal cortex (DLPFC) from schizophrenia (SCHIZ), bipolar (BD), and normal control cohorts from the Harvard Brain Tissue Resource Center performed using ProteinChip technology based on the surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS). The resultant profiles were utilized in classification-tree algorithms for selection of protein biomarker peaks contributing maximally to the differentiation between the examined diagnostic cohorts. Twenty-four such protein biomarker peaks were identified. All of them had lower levels in the SCHIZ cohort as compared to the BD cohort. Also, 21 of these peaks were down-regulated in the SCHIZ cohort vs. the control cohort, and 7 peaks were up-regulated in the BD cohort vs. the control cohort. The proteins constituting these biomarker peaks were recognized via matrix-assisted laser desorption time of flight/postsource decay mass spectrometry (MALDI-TOF-PSD-MS). These proteins represent a wide range of functional groups involved in cell metabolism, signaling cascades, regulation of gene transcription, protein and RNA chaperoning, and other aspects of cellular homeostasis. Finally, after statistical evaluation suggesting that the selected protein biomarkers are not significantly impacted by epidemiological/tissue storage parameters (although, influence of antipsychotic and mood stabilizing drugs could not be fully excluded), the ProteinChip-based profiling was engaged again to demonstrate that the detected SCHIZ-associated changes in the levels of our protein biomarkers could also be seen in DLPFC samples from the brain collection of the Mount Sinai Medical School/Bronx Veteran Affairs Medical Center. This study demonstrates the usefulness of ProteinChip-based SELDI-TOF protein profiling in gaining insight into the molecular pathology of SCHIZ and BD as it points to changes in protein levels characterizing these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparing protein abundance and mRNA expression levels on a genomic scale
Greenbaum, D. (2003) · Genome biology · doi:10.1186/gb-2003-4-9-117 · Cited by 1,692 · cited 2×
“It is well known, however, that mRNA expression levels do not necessarily translate into a proportional protein abundance (Greenbaum et al., 2003); yet, presently there are very few studies employing high-throughput protein profiling of brain tissue from SCHIZ and/or BD patients (Johnston-Wilson et…”
ResultMetabolic coupling between glia and neurons
Tsacopoulos, M., & Magistretti, P. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-03-00877.1996 · Cited by 1,006
Mirnics, K., Middleton, F. A., Marquez, A., Lewis, D. A., & Levitt, P. (2000) · Neuron · doi:10.1016/s0896-6273(00)00085-4 · Cited by 882 · cited 1×
“…of high-throughput genomic studies in brain tissue from SCHIZ and BD patients (Aston et al., 2004; Chung et al., 2003; Hakak et al., 2001; Iwamoto et al., 2005a,b; Middleton et al., 2002, 2005; Mirnics et al., 2000, 2001; Pongrac et al., 2004; Tkachev et al., 2004; Vawter et al., 2001, 2002).”
BackgroundMultiple-laboratory comparison of microarray platforms
Irizarry, R. A., Warren, D., Spencer, F., Kim, I. F., Biswal, S., Frank, B. C., Gabrielson, E., Garcia, J. G. N., Geoghegan, J., Germino, G., et al. (2005) · Nature Methods · doi:10.1038/nmeth756 · Cited by 862 · cited 1×
“Recently, similar to that for DNA microarrays (Bammler et al., 2005; Irizarry et al., 2005; Wang et al., 2005), concerns have been raised regarding inter-and intralaboratory reproducibility of Protein Chip arrays (Baggerly et al., 2004; Diamandis, 2004).”
BackgroundA Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598 · cited 1×
“Finally, two SCHIZ-affected protein biomarkers (CALM1 and (14-3-3) activate the rate-limiting enzyme in dopamine synthesis, tyrosine hydroxylase (Perez et al., 2002; Berg et al., 2003), while another protein biomarker (DECR2) influences the presynaptic pool of dopaminergic vesicles (Logan, 2004).”
BackgroundDisease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., & Levitt, P. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000866 · Cited by 446 · cited 2×
“…of high-throughput genomic studies in brain tissue from SCHIZ and BD patients (Aston et al., 2004; Chung et al., 2003; Hakak et al., 2001; Iwamoto et al., 2005a,b; Middleton et al., 2002, 2005; Mirnics et al., 2000, 2001; Pongrac et al., 2004; Tkachev et al., 2004; Vawter et al., 2001, 2002).”
BackgroundBazan, N. G. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300013-jlr200 · Cited by 247
Progress in the use of microarray technology to study the neurobiology of disease
Mirnics, K., & Pevsner, J. (2004) · Nature Neuroscience · doi:10.1038/nn1230 · Cited by 150 · cited 2×
“…diseases, together with the availability of sequences for the full human genome (reviewed in: Rogers, 2003) and development of DNA microarrays (Mirnics and Pevsner, 2004; Ryan et al., 2004), has resulted in an explosion of high-throughput genomic studies in brain tissue from SCHIZ and BD…”
Background
Cited by
Extracellular matrix abnormalities in schizophrenia
Berretta, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.010 · Cited by 179
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Föcking, M., Dicker, P., English, J. A., Schubert, K. O., Dunn, M. J., & Cotter, D. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.43 · Cited by 90
(2009) · PubMed · Cited by 31
Metadata
- Authors
- Novikova, S. I., He, F., Cutrufello, N. J., & Lidow, M. S.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 23
- Issue
- 1
- Pages
- 61-76
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2013224236
- Cited by
- 82
- References
- 8
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. https://app.cochat.ai/papers/10.1016/j.nbd.2006.02.002
- The paper
- Novikova, S. I., He, F., Cutrufello, N. J., & Lidow, M. S. (2006). Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2006.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.